Unlisted Options Transactions, page-174

There is already data demonstrating anti-PD1 therapies synergise with the FTO inhibitor DAC51.

https://www.sciencedirect.com/science/article/abs/pii/S1550413121001674

From the graphs below you'll notice that when the combination is used the tumor volume shrinks to almost nothing (F) and approximately 70% of mice survive (G), which is a great improvement on the control and if each treatment is used in isolation.



So, there are papers demonstrating FTO KD models and an inferior FTO inhibitor synergise with anti-PD1 treatment in animal models. I'd say the chance of Zantrene synergising with an anti-PD1 is extremely high, and as such have instead directed my attention to which commercially available anti-PD1 might synergise.